Ophthalmic therapeutic composition
AssigneeNihon Tenganyaku Kenkyusho Co., LTD.
InventorsTeruo Nishida, Yorihisa Uetake, Hiroaki Iwata
Life of this patent
Estimating the term…
Abstract
An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1)(Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.
Claims8
An ophthalmological composition, containing, as an effective component, the peptide, PHSRN (SEQ ID NO:
- 1), or a salt of this peptide that is allowable as a medical drug.
Either or both of a corneal disorder preventive agent and a corneal disorder treatment agent, having, as an effective component, the peptide, PHSRN (SEQ ID NO:
- 1), or a salt of this peptide that is allowable as a medical drug.
A corneal epithelium migration promoting agent having, as an effective component, the peptide, PHSRN (SEQ ID NO:
- 1), or a salt of this peptide that is allowable as a medical drug.
Usage of an effective amount of the peptide, PHSRN (SEQ ID NO:
- 1), or a salt of this peptide that is allowable as a medical drug and a corneal disorder treatment method based on such usage.
Dependencies are inferred from the claim text.